Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Guangzhou Innogen Pharmaceutical Group / Equity Capital Markets

<ul>
<li>Innogen, a China-based near-commercial stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. CITIC Securities and CICC are the joint sponsors.</li>
<li>In this note, we look at changes to the company’s PHIP prospectus.</li>
<li>While there is no major update to the asset lists, we do see that the market forecasts provided in the prospectus scaled down significantly.</li>
</ul>


Innogen, a China-based near-commercial stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. CITIC Securities and CICC are the joint sponsors.
In this note, we look at changes to the company’s PHIP prospectus.
While there is no major update to the asset lists, we do see that the market forecasts provided in the prospectus scaled down significantly.


Innogen (银诺医药) Pre-IPO Update: Cuts in Market Forecasts

<ul>
<li>Innogen, a China-based near-commercial stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. CITIC Securities and CICC are the joint sponsors.</li>
<li>In this note, we look at changes to the company’s refiled application proof.</li>
<li>We also did a comparison between the company’s product and PegBio’s PB-119. PegBio was listed on HKEx in May. We also check its products’ online listing.</li>
</ul>


Innogen, a China-based near-commercial stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. CITIC Securities and CICC are the joint sponsors.
In this note, we look at changes to the company’s refiled application proof.
We also did a comparison between the company’s product and PegBio’s PB-119. PegBio was listed on HKEx in May. We also check its products’ online listing.


Innogen (银诺医药) Pre-IPO Update: New Data Points

HK/China Equity Long-Short

Osbert Tang, CFA

Equity Bottom-Up

China International Capital Corporation / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/china-international-capital-corporation-ltd" target="_blank" data-smartkarma-citation="entities:1071:1" rel="noopener">China International Capital Corporation (3908 HK)</a>'s 1H25 positive profit alert is encouraging, with 1H25 results growing by 55-78% YoY.  </li>
<li>YTD, CICC has a 59.5% share of the HK IPO market. The solid H-share IPO pipeline of A-share companies is beneficial, as this is its major area of strength.</li>
<li>Market consensus has underestimated its FY25 earnings, inflating its PER multiples. The current 51% discount of its H-share to A-share is just too steep (average 37.7%).</li>
</ul>



China International Capital Corporation (3908 HK)'s 1H25 positive profit alert is encouraging, with 1H25 results growing by 55-78% YoY.  
YTD, CICC has a 59.5% share of the HK IPO market. The solid H-share IPO pipeline of A-share companies is beneficial, as this is its major area of strength.
Market consensus has underestimated its FY25 earnings, inflating its PER multiples. The current 51% discount of its H-share to A-share is just too steep (average 37.7%).


CICC (3908 HK): It Is the Best of the Time

<ul>
<li>Medtide raised HKD 514m (USD 65.5m) from its global offering and will list on the Hong Kong Stock Exchange on Monday, June 30th.</li>
<li>In our previous note, we looked at the company's operation, management track records and discussed the IPO valuation.</li>
<li>In this note, we provide an update for the IPO before trading debut. </li>
</ul>


Medtide raised HKD 514m (USD 65.5m) from its global offering and will list on the Hong Kong Stock Exchange on Monday, June 30th.
In our previous note, we looked at the company's operation, management track records and discussed the IPO valuation.
In this note, we provide an update for the IPO before trading debut. 


Medtide (泰德医药) IPO Trading Update

<ul>
<li>Innogen, a China-based near-commercial stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. CITIC Securities and CICC are the joint sponsors.</li>
<li>In this note, we look at the company’s product pipeline, its pre-IPO investors, and management.</li>
<li>Our initial view is that the stock will rely heavily on its sales ramp. Yet we are not seeing signs that the company is at full throttle post-NMPA approval.</li>
</ul>


Innogen, a China-based near-commercial stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. CITIC Securities and CICC are the joint sponsors.
In this note, we look at the company’s product pipeline, its pre-IPO investors, and management.
Our initial view is that the stock will rely heavily on its sales ramp. Yet we are not seeing signs that the company is at full throttle post-NMPA approval.


Innogen (银诺医药) Pre-IPO First Take: Good News Is Also Bad News

China

PegBio Co., Ltd. conducts biotechnology businesses. The Company develops innovative treatments for chronic diseases and metabolic diseases. PegBio provides its services throughout Japan.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

PegBio (2565 HK)

Innogen (银诺医药) Pre-IPO Update: Cuts in Market Forecasts

China biotech company Innogen plans to raise $100 million in Hong Kong listing with CITIC Securities and CICC as joint sponsors, with scaled down...

Ke Yan, CFA, FRM

Innogen (银诺医药) Pre-IPO Update: New Data Points

China-based biotech company Innogen seeks to raise $100 million through Hong Kong listing. We look at updates from the company's latest prospectus...

Ke Yan, CFA, FRM

CICC (3908 HK): It Is the Best of the Time

CICC is alerting a strong 1H25 profit growth, leading in the HK IPO market with a promising H-share IPO pipeline of A-share companies. The market...

Osbert Tang, CFA

Medtide (泰德医药) IPO Trading Update

Medtide raises $65.5m in global offering, set to list on Hong Kong Stock Exchange June 30th. We provide an update prior to trading debut on Monday.

Ke Yan, CFA, FRM

Innogen (银诺医药) Pre-IPO First Take: Good News Is Also Bad News

Innogen, the leading Chinese company in the GLP-1 space, seeks to raise $100 million through Hong Kong listing, with focus on product pipeline and...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Innogen (银诺医药) Pre-IPO Update: Cuts in Market Forecasts

​China biotech company Innogen plans to raise $100 million in Hong Kong listing with CITIC Securities and CICC as joint sponsors, with scaled down...

Ke Yan, CFA, FRM

Innogen (银诺医药) Pre-IPO Update: New Data Points

​China-based biotech company Innogen seeks to raise $100 million through Hong Kong listing. We look at updates from the company's latest prospectus...

Ke Yan, CFA, FRM

CICC (3908 HK): It Is the Best of the Time

​CICC is alerting a strong 1H25 profit growth, leading in the HK IPO market with a promising H-share IPO pipeline of A-share companies. The market...

Osbert Tang, CFA

Medtide (泰德医药) IPO Trading Update

​Medtide raises $65.5m in global offering, set to list on Hong Kong Stock Exchange June 30th. We provide an update prior to trading debut on Monday.

Ke Yan, CFA, FRM

Innogen (银诺医药) Pre-IPO First Take: Good News Is Also Bad News

Innogen, the leading Chinese company in the GLP-1 space, seeks to raise $100 million through Hong Kong listing, with focus on product pipeline and...

Ke Yan, CFA, FRM

China biotech company Innogen plans to raise $100 million in Hong Kong listing with CITIC Securities and CICC as joint sponsors, with scaled down...

China-based biotech company Innogen seeks to raise $100 million through Hong Kong listing. We look at updates from the company's latest prospectus...

CICC is alerting a strong 1H25 profit growth, leading in the HK IPO market with a promising H-share IPO pipeline of A-share companies. The market...

Medtide raises $65.5m in global offering, set to list on Hong Kong Stock Exchange June 30th. We provide an update prior to trading debut on Monday.